PA-SYNERGIS-SOFTWARE
9.3.2022 15:24:09 CET | Business Wire | Press release
Synergis Software, a global leader in engineering document management and workflow solutions, today announced a rebrand and new website in synchrony with major investments in product development and customer success. These initiatives will fast track the company’s delivery of superior products and services to their global customer base.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220309005289/en/
“We see so much opportunity to have a positive impact on the customers we serve, which is why we’re making major investments in the company," states Scott Lamond, vice president of marketing at Synergis Software. "We want our brand to align with our mission of transforming the way our customers work— providing greater clarity, control, alignment, and harmony—so they can accelerate engineering projects, streamline operations, reduce risk, and lower costs." Watch the rebrand video .
The Adept platform is used by 120,000 users worldwide, including Dow Chemical, Con Edison, Amazon, Merck, and General Mills, and is managing over $1B in digital assets.
“Adept manages billions of dollars of digital assets containing priceless Dow intellectual property, with thousands of users across several dozen global sites," says Teresa Yang, Product Manager, Document Management, Dow Chemical.
Synergis is committed to accelerating the company’s growth and elevating the value delivered to customers with significant investments in their products.
“We’re tripling the size of our software development organization. By the end of 2022, our team will have grown by 218% in just two years,” explains Todd Cummings, vice president of research and development at Synergis. “The added positions include developers, QA staff, product managers, DevOps, SCRUM Masters, and User Experience professionals. Key leaderships roles are in place to help us refine the processes, tools, and methods we use to develop and deliver more value, faster.”
Synergis is investing substantially in the Adept platform, including the upcoming release of a new, integrated visualization solution for 2D and 3D engineering designs and other document types, along with major new feature enhancements and support for new versions of mainstream CAD systems. A new Cloud version of Adept is underway for customers who want to lower their IT costs and simplify deployment and upgrades.
“We’ll continue to build on Synergis Software’s legacy of extraordinary, love-based service and treating customers like family," adds Lamond. Toward that end, Synergis is expanding its customer success team, developing an online “Adept Academy”, and launching three new services options, including:
- Ongoing Technical Consulting - Customers can work one-on-one with a dedicated Adept technical consultant on a regular basis to improve their Adept environment, streamline processes, remove roadblocks, and increase the value of Adept to their organization. Synergis experts will provide strategic and technical guidance on nearly any type of project to help customers reach their goals.
- Remote Adept Administration - Customers can outsource the day-to-day application management and administration of Adept to our experienced technical staff to keep their resources focused on what’s most important to their business. Our managed services will help keep our customer’s Adept environment optimized and lower operating costs.
- Adept Server Hosting - Customers can outsource the hosting of their entire Adept Server environment to free up IT resources, lower operating costs, and improve security.
Synergis Software’s focus and investments in service and support will help maintain their strong leadership position in the market, as validated in the rankings on the G2 software review site.
“We couldn’t have arrived at this moment without 30 years of thoughtful, collaborative, and visionary support from our customer community and the individuals who have shaped us,” added Lamond. “We’re grateful for their influence as we build our future together.”
About Synergis Software
Synergis Software is a global leader in document management and workflow solutions and is the creator of Synergis Adept software. Adept serves more than 120,000 users across dozens of industries providing fast, centralized access to design and business documents in a secure, collaborative environment. Adept Integrator connects enterprise applications so critical data and business processes can flow seamlessly across the entire IT infrastructure.
Named the customer service leader in the global engineering information management market by Frost & Sullivan and ranked in the Top 5 globally by Helpdesk International for three consecutive years, the company's commitment to its customers is unwavering.
Founded in 1985, Synergis Technologies, LLC is headquartered in Bucks County, PA and is privately owned and funded. For more information, visit SynergisSoftware.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220309005289/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom